Chuck Triano | Head of Investor Relations |
Christopher Viehbacher | President and Chief Executive Officer |
Priya Singhal | Head of Development and Interim Head of Research |
Michael McDonnell | Chief Financial Officer |
Brian Abrahams | RBC Capital Markets |
Marc Goodman | Leerink Partners |
Robyn Karnauskas | Truist Securities |
Mohit Bansal | Wells Fargo |
Umer Raffat | Evercore ISI |
Salveen Richter | Goldman Sachs |
Michael Yee | Jefferies |
Tim Anderson | Wolfe Research |
Evan Seigerman | BMO Capital Markets |
Ami Fadia | Needham and Company |
Brian Skorney | Robert W. Baird and Company |
Chris Schott | JPMorgan |
Paul Matteis | Stifel |
Good morning. My name is Ruth and I'll be your conference operator today. At this time, I would like to welcome everyone to the Biogen's Second Quarter 2023 Earnings Call and Business Update. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session.